Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome
- PMID: 19366799
- DOI: 10.1158/0008-5472.CAN-08-3907
Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome
Abstract
Post-translational histone modifications are known to be altered in cancer cells, and loss of selected histone acetylation and methylation marks has recently been shown to predict patient outcome in human carcinoma. Immunohistochemistry was used to detect a series of histone lysine acetylation (H3K9ac, H3K18ac, H4K12ac, and H4K16ac), lysine methylation (H3K4me2 and H4K20me3), and arginine methylation (H4R3me2) marks in a well-characterized series of human breast carcinomas (n = 880). Tissue staining intensities were assessed using blinded semiquantitative scoring. Validation studies were done using immunofluorescence staining and Western blotting. Our analyses revealed low or absent H4K16ac in the majority of breast cancer cases (78.9%), suggesting that this alteration may represent an early sign of breast cancer. There was a highly significant correlation between histone modifications status, tumor biomarker phenotype, and clinical outcome, where high relative levels of global histone acetylation and methylation were associated with a favorable prognosis and detected almost exclusively in luminal-like breast tumors (93%). Moderate to low levels of lysine acetylation (H3K9ac, H3K18ac, and H4K12ac), lysine (H3K4me2 and H4K20me3), and arginine methylation (H4R3me2) were observed in carcinomas of poorer prognostic subtypes, including basal carcinomas and HER-2-positive tumors. Clustering analysis identified three groups of histone displaying distinct pattern in breast cancer, which have distinct relationships to known prognostic factors and clinical outcome. This study identifies the presence of variations in global levels of histone marks in different grades, morphologic types, and phenotype classes of invasive breast cancer and shows that these differences have clinical significance.
Similar articles
-
Epigenetic modulation of BRCA-1 and MGMT genes, and histones H4 and H3 are associated with breast tumors.J Cell Biochem. 2019 Aug;120(8):13726-13736. doi: 10.1002/jcb.28645. Epub 2019 Apr 2. J Cell Biochem. 2019. PMID: 30938887 Clinical Trial.
-
An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression.Breast Cancer Res Treat. 2012 Jun;133(3):959-68. doi: 10.1007/s10549-011-1871-x. Epub 2011 Nov 20. Breast Cancer Res Treat. 2012. PMID: 22101407
-
Association of global levels of histone modifications with recurrence-free survival in stage IIB and III esophageal squamous cell carcinomas.Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):566-73. doi: 10.1158/1055-9965.EPI-09-0980. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20142251
-
The role of histone modifications and variants in regulating gene expression in breast cancer.J Mammary Gland Biol Neoplasia. 2010 Mar;15(1):19-33. doi: 10.1007/s10911-010-9167-z. Epub 2010 Feb 4. J Mammary Gland Biol Neoplasia. 2010. PMID: 20131086 Review.
-
Acetylation of Histone H3 in Cancer Progression and Prognosis.Int J Mol Sci. 2024 Oct 12;25(20):10982. doi: 10.3390/ijms252010982. Int J Mol Sci. 2024. PMID: 39456765 Free PMC article. Review.
Cited by
-
Histone modifications and cancer: biomarkers of prognosis?Am J Cancer Res. 2012;2(5):589-97. Epub 2012 Aug 20. Am J Cancer Res. 2012. PMID: 22957310 Free PMC article.
-
Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges.Front Pharmacol. 2024 Jan 9;14:1260276. doi: 10.3389/fphar.2023.1260276. eCollection 2023. Front Pharmacol. 2024. PMID: 38264526 Free PMC article. Review.
-
Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.Front Oncol. 2024 Jul 26;14:1405267. doi: 10.3389/fonc.2024.1405267. eCollection 2024. Front Oncol. 2024. PMID: 39132504 Free PMC article.
-
Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer.Int J Mol Sci. 2022 Aug 23;23(17):9521. doi: 10.3390/ijms23179521. Int J Mol Sci. 2022. PMID: 36076918 Free PMC article. Review.
-
Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.J Nat Sci. 2015;1(7):e127. J Nat Sci. 2015. PMID: 26082944 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials